Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929392 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
A Phase 2 study of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT04929392 is a Phase 2 study of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 3 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04929392, a Phase 2 study of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic). Pembrolizumab is an immunotherapy drug that works by harnessing the immune system to attack cancer. Lenvatinib is an anti-cancer drug that works by stopping or slowing down the growth of cancer cells. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Carboplatin
- RADIATION External Beam Radiation Therapy
- DRUG Paclitaxel
- DRUG Lenvatinib Mesylate
- PROCEDURE Endoscopic Biopsy
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2027-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04929392
The ClinicalTrials.gov registry entry for NCT04929392 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (99% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04929392 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04929392 about?
NCT04929392 is a clinical study titled "Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer". This phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic). Pembrolizumab is an...
What is the current status of trial NCT04929392?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-01-25. Estimated completion is 2027-04-25.
What conditions does trial NCT04929392 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8.
What interventions are being tested in trial NCT04929392?
The interventions under investigation include: Carboplatin (DRUG), External Beam Radiation Therapy (RADIATION), Paclitaxel (DRUG), Lenvatinib Mesylate (DRUG), Endoscopic Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04929392?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929392 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
RECRUITING · Phase 2
-
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Obeticholic Acid for Prevention in Barrett's Esophagus
RECRUITING · Phase 2
Explore more on PlainTrial
Esophageal Adenocarcinoma
All registered trials for this condition
Esophageal Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.